Sagedal S, Hartmann A, Rollag H
Department of Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway.
Clin Microbiol Infect. 2005 Jul;11(7):518-30. doi: 10.1111/j.1469-0691.2005.01190.x.
Human cytomegalovirus (HCMV) infection is the single most frequent infectious complication in the early period after kidney transplantation. The HCMV load in blood, measured by HCMV PCR or the HCMV pp65 antigen test, is a predictor of HCMV disease in seropositive recipients. However, plasma virus load measurements are of only modest value in predicting the risk of HCMV disease in seronegative recipients of kidneys from seropositive donors. HCMV infection is an independent risk-factor for acute kidney graft rejection. There is also evidence that HCMV is associated with an increased long-term mortality and post-transplant diabetes mellitus. Whether pre-emptive or prophylactic therapy should be the preferred strategy is not yet decided. Some studies indicate that HCMV prophylaxis may reduce the risk of acute rejection, and thereby increase long-term graft survival in seronegative recipients of kidneys from seropositive donors.
人巨细胞病毒(HCMV)感染是肾移植术后早期最常见的感染并发症。通过HCMV PCR或HCMV pp65抗原检测测得的血液中HCMV载量,是血清反应阳性受者发生HCMV疾病的一个预测指标。然而,血浆病毒载量检测在预测血清反应阴性的肾移植受者(供者为血清反应阳性)发生HCMV疾病风险方面价值有限。HCMV感染是急性肾移植排斥反应的一个独立危险因素。也有证据表明,HCMV与长期死亡率增加及移植后糖尿病有关。究竟应首选抢先治疗还是预防性治疗策略尚未确定。一些研究表明,HCMV预防可能会降低急性排斥反应的风险,从而提高血清反应阴性的肾移植受者(供者为血清反应阳性)的长期移植肾存活率。